Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies (DyNaMic)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04743557
Recruitment Status : Not yet recruiting
First Posted : February 8, 2021
Last Update Posted : April 23, 2021
Sponsor:
Information provided by (Responsible Party):
Dynacure

Brief Summary:
There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety and tolerability as well as pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of DYN101 in participants 2 to 17 years of age with CNM caused by mutations in DNM2 or MTM1.The trial will consist of a pre-screening consent, a screening period, a run-in period (if applicable), and a Part 1 of 12 weeks with weekly infusion of DYN101 to evaluate safety and tolerability as well as PK, PD and preliminary efficacy. The dose level may need adjustment based on the Part 1 results of the current study and available data from the Unite-CNM study (DYN101-C101, NCT04033159). If a dose adjustment is needed, Part 2 will be conducted in the same participants and the newly selected dose level will be used to assess whether efficacy is seen after an additional 12 weeks of treatment. As this trial is investigational, there is no defined, expected benefit for subjects who participate in this trial except a better knowledge of their disease.

Condition or disease Intervention/treatment Phase
Centronuclear Myopathy Drug: DYN101 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Multicenter, Open-label, Dose-confirmation Trial to Evaluate the Safety and Preliminary Efficacy of DYN101 in Participants 2 to 17 Years of Age With Centronuclear Myopathy Caused by Mutations in MTM1 or DNM2
Estimated Study Start Date : October 2021
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : June 2023


Arm Intervention/treatment
Experimental: Cohort 1
Weekly infusions of DYN101 at the starting dose level
Drug: DYN101
DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA




Primary Outcome Measures :
  1. Incidence of drug-related Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Baseline until Week 12 ]

Secondary Outcome Measures :
  1. Measurement of DYN101 concentration in plasma [ Time Frame: Week 1 Day 1: before the start of infusion (baseline), immediately after the end of infusion, and at 1, 3, 7, 23, 71 hours after the end of infusion. Week 13 Day 1: predose and 3 hours after the end of infusion ]
  2. Maximum plasma drug concentration (Cmax) for DYN101 [ Time Frame: Week 1 Day 1: before the start of infusion (baseline), immediately after the end of infusion, and at 1, 3, 7, 23, 71 hours after the end of infusion. Week 13 Day 1: predose and 3 hours after the end of infusion ]
  3. Area under the Plasma Concentration versus Time Curve (AUC) of DYN101 [ Time Frame: Week 1 Day 1: before the start of infusion (baseline), immediately after the end of infusion, and at 1, 3, 7, 23, 71 hours after the end of infusion. Week 13 Day 1: predose and 3 hours after the end of infusion ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female aged ≥2 to <18 years on the date the main ICF is signed.
  2. Have a clinically symptomatic CNM, with a documented MTM1 or DNM2 mutation.
  3. Have impaired muscle function as evidenced by:

    • MFM20 score between 5% and 80% for subjects ≥2 and <6 years of age, or
    • MFM32 score between 5% and 80% for subjects ≥6 years of age.
  4. Have sufficient skeletal muscle (vastus lateralis, gastrocnemius, or biceps brachii as last resort) to perform 2 open muscle biopsies during the trial, as determined by ultrasound imaging at screening.
  5. Subject must have platelet count >150,000/µL at screening.
  6. Parent(s) or legally-authorized representative must be able to provide written, signed and dated informed consent for their child to participate in the trial. Informed assent can be obtained from the child according to local regulations.
  7. Parent(s) or legally-authorized representative must be at or above the age of legal consent in the jurisdiction of the country in which the trial is taking place.
  8. Subject, parent(s), and/or legally-authorized representative must have an understanding, ability, and willingness to fully comply with visit frequency, trial procedures, videorecording of assessments where applicable, and restrictions, including contraceptive requirements.

Exclusion Criteria:

  1. Subject has evidence of clinically significant liver disease.
  2. Subject has evidence of clinically significant renal disease.
  3. Presence of significant comorbidities or conditions other than CNM or clinically significant findings during screening of medical history, physical examination, clinical laboratory evaluation, vital signs, or ECG recording for which, in the opinion of the investigator and/or the medical monitor, participation would not be in the best interest of the subject (e.g. compromise the safety or well-being) or that could prevent, limit, or confound the protocol-specified assessments (e.g. taking a muscle biopsy).
  4. Subject currently enrolled in any interventional trial or scheduled to participate in such a trial whilst participating in the current trial.
  5. Subject has previously received gene therapy for CNM.
  6. Subject has severe muscle contractures that would preclude the ability to show improvement in the MFM32 assessment, in the opinion of the investigator.
  7. Subject has severe airway malacia which could impact the capacity to wean off ventilatory support.
  8. Subject requires oxygen supplementation.
  9. For female subjects of childbearing potential: pregnant, breastfeeding, or planning to become pregnant during the trial.
  10. Current or relevant history of physical or psychiatric illness, and/or any medical disorder that may require treatment or make the subject unlikely to fully complete the trial, or any condition that presents undue risk from the investigational medicinal product (IMP) or procedures.
  11. Intake of any disallowed therapies by the subject within 12 weeks before the planned first IMP administration.
  12. Known or suspected intolerance or hypersensitivity to IMP ingredients or closely related compounds.
  13. Parent(s) or legally authorized representative are legally incapacitated or have limited legal capacity, or have lack of mental capacity to fully understand the protocol requirements and ensure completion of all required trial procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04743557


Contacts
Layout table for location contacts
Contact: Chris Freitag, MD chris.freitag@dynacure.com

Locations
Layout table for location information
France
I-Motion Institute - Trousseau Hospital
Paris, France, 75012
Contact: Emmanuelle Lagrue, MD    +33 1 44 73 65 44    e.lagrue@institu-myologie.org   
Germany
Universitätsklinikum Essen
Essen, Germany, 45122
Contact: Ulrike Schara-Schmidt, Prof. Dr.    +49 201 7232508    ulrike.schara@uk-essen.de   
Sponsors and Collaborators
Dynacure
Publications:
Layout table for additonal information
Responsible Party: Dynacure
ClinicalTrials.gov Identifier: NCT04743557    
Other Study ID Numbers: DYN101-C102
2020-004608-32 ( EudraCT Number )
First Posted: February 8, 2021    Key Record Dates
Last Update Posted: April 23, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dynacure:
Muscular Diseases
Myopathies, Structural, Congenital
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Diseases
Myopathies, Structural, Congenital
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases